Humacyte Inc. (HUMA)
HUMA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.3589
-7.88% on the day
Market cap
$99.7M
Micro cap
Revenue · 2025
$2.0M
Prior year not contiguous
Net income · 2025
-$40.8M
-2003.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | HUMA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001818382 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.0M |
| Net income | -$40.8M |
| Operating income | -$108.1M |
| Net margin | -2003.6% |
| Operating margin | -5306.0% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $50.5M |
| Total assets | $116.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 48.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-11 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-08-12 |
| Latest current report | 8-K | 2026-09-28 |
| Latest proxy | DEF 14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 504 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics Inc. | $1.68 | -5.08% | $96.5M |
| ATRA | Atara Biotherapeutics Inc. | $9.30 | -0.80% | $93.4M |
| LENZ | LENZ Therapeutics Inc. | $3.40 | -5.82% | $106.8M |
| ENGN | enGene Therapeutics Inc. | $1.63 | -4.12% | $109.2M |
| ARMP | Armata Pharmaceuticals Inc. | $3.10 | -14.60% | $115.3M |
| TNYA | Tenaya Therapeutics Inc. | $0.5210 | -7.87% | $116.8M |
| CRDF | Cardiff Oncology Inc. | $1.01 | -2.88% | $78.6M |
| PTHS | Pelthos Therapeutics Inc. | $20.29 | +3.94% | $77.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier